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Abstract 
 
Delivery of anti-cancer drugs using graphene and its derivatives: graphene oxide (GO) 
and reduced graphene oxide (RGO) has sparked major interest in this emerging field. 
The anti-cancer therapies often pose a limitation of insolubility, administration 
problems and cell-penetration ability. In addition, systemic toxicity caused by lack of 
selective targeting towards cancer cells and inefficient distribution limits its clinical 
applications. Graphene nanocomposite is a promising tool to address these drawbacks. 
Graphene is a flat monolayer of carbon atoms that holds many promising properties 
such as unparalleled thermal conductivity, remarkable electronic properties, and most 
intriguingly high planar surface and superlative mechanical strength, which are 
attractive in biotechnology applications. 
However the synthesis route for the production of GO or RGO often involves the use 
of harsh chemicals which jeopardize its further application as a drug delivery cargo. 
To overcome these limitations, a simple one-pot strategy was used to synthesize RGO 
nanosheets by utilizing an easily available over-the-counter medicinal and edible 
mushroom, Ganoderma lucidum. The produced RGO was readily dispersible in water 
and various solvents. The RGO was highly biocompatible towards colon (HT-29), 
brain (U87MG) and normal cells (MRC-5). By functionalization of RGO with an 
amphiphilic polymer, PF-127, a more stable RGO was produced, called GP. 
Curcumin (Cur) and Paclitaxel (Ptx) was then loaded onto the GP cargo, resulting in a 
nano-sized GP-Cur-Ptx sytem with the particle size of 140 nm. A remarkably high 
drug loading was also achieved with 678 wt.%, highest thus far, compared to any 
other Cur nanoformulations. Based on cell proliferation assay, the GP-Cur-Ptx is a 
synergistic treatment and is highly potent towards A549 (lung) and MDA-MB-231 
(breast) cancer cells. These positive findings are further confirmed by increased 
reactive oxygen species (ROS); mitochondrial membrane potential (MMP) depletion; 
and cell apoptosis. The same treated with normal cells (MRC-5) shows that the 
system is biocompatible and cell-specific.  
Keywords: reduced graphene oxide, synergistic treatment, A549, MDA-MB-231, 
Curcumin, Paclitaxel 
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GO 
 
graphene oxide 
 
GP 
 
polymer functionalized RGO 
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MMP 
 
mitochonria membrane potential  
 
MRC-5 
 
normal human cells 
 
MTT 
 
3-(4,5-dimethylthiazol-2-yl)-2,5-
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1.0 Introduction 
 
Graphene, a ‘wonder material’ of this decade has gained tremendous interest from 
researchers across the globe since its discovery in 2004, using a sticky tape and a 
pencil [1]. Graphene is a two-dimensional (2D) sheet with one atom thickness and 
consists of sp
2
 hybridized carbon atoms, arranged in a honeycomb network [2]. It is 
also the building block of other carbon allotropes, whereby wrapping of graphene 
forms 0D fullerene [3], rolling forms 1D carbon nanotubes (CNTs), and stacking can 
produce 3D graphite [4]. 
In this short period of time, extensive research has been carried out on graphene and 
its derivatives, with the number of publications exceeding 23,000 (Science Direct), 
closely catching up on CNTs’ 33,000 publications, which was discovered back in 
1991 [5]. The explosion of interest in this new nanomaterial is due to its properties 
such as superlative mechanical strength (Young’s modulus of 1100 GPa) [6], 
unparalleled thermal conductivity (5000 W/m/K) [7], electrical conductivity (mobility 
of charge carriers of 200,000 cm
2
V
-1
s
-1
) [8,9], high planar surface area (2630 m
2
/g) 
[6], ease of functionalization [10,11], low cost and easy scalability on its production 
[12-15].   
As graphene research has expanded, many potential applications were discovered 
such as new energy storage devices, sensors, transparent electrodes, photodetectors 
[6,16-18], as well as recent advances in medical applications such as drug or gene 
delivery, biosensor, medical imaging, tissue engineering, photothermal therapy, 
antibacterial applications and water treatment [2,14,15,19-26].  
Graphene oxide (GO) and reduced graphene oxide (RGO) is part of the graphene 
family, besides other derivatives such as graphene nanosheets, few-layer graphene 
and ultrathin graphite [27]. GO, in particular is the most researched material in the 
graphene family due to its ease of functionalization. GO consists of carboxylate 
groups on the periphery as well as epoxide, hydroxyl and graphenic domains on the 
basal plane. The graphenic domain exhibits hydrophobicity and displays pi-pi  
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interactions with other aromatic molecules, whereas the remaining functional groups 
provide hydrophilicity. However, most of the routes for synthesizing GO involve 
strong oxidizing agents which are ultimately carried forward to the end-product. 
Moreover, GO is highly acidic which could cause damage to the normal cells, thus 
jeopardizing its role as a carrier in drug delivery system. Moreover, presence of 
hydroxyl and epoxide groups on the basal plane in GO hinders effective pi-pi 
interactions with other aromatic molecules due to steric hindrance, as compared to 
preferable drug carrying capacity in RGO (Figure 1) [28,29]. 
On the other hand, RGO is the reduced form of GO that contains only the graphenic 
domains on the basal plane, without any oxygen functional groups. Hence, RGO is 
hydrophobic and tends to agglomerate irreversibly or even transforms back to graphite 
due to its van der Waals’ interaction and its stronger π-π stacking, which limits its 
further applications. Therefore, the route of synthesis of RGO is of vital importance to 
impart stability as most of its unique electrical and mechanical properties are 
associated only with the individualised graphene sheets [30-32]. In addition, 
imparting solubility in water is also crucial as a well-dispersed RGO would allow 
further functionalization and open opportunities for various technological 
applications.    
 
Figure 1 Graphical illustration of GO and RGO. 
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Several methods have been reported to obtain RGO such as micromechanical 
cleavage [1], epitaxial growth [33], chemical vapour deposition (CVD) [34], un-
zipping of carbon nanotubes (CNTs) [35] and chemical reduction of GO [36]. 
Micromechanical method suffers from low yield and hinders large scale applications 
[37]; the epitaxial growth method produces graphene with random and uncontrollable 
thickness [4]; whereas the methods of CVD and un-zipping of CNTs involve using 
several chemicals and lengthy reaction steps. Hence, much focus has been emphasized 
on solution-based reduction of GO which generally produces single to few-layer 
graphene sheets. Conventional thermal reduction, however requires higher 
temperatures and pressures for the removal of intercalated water molecules and oxide 
functional groups such as epoxides, hydroxides and carboxylic acids [37,38]. In 
addition, it requires a specific reaction vessel and may cause environmental and 
economic concerns when large scale production is considered.   
Therefore, researchers are more intrigued in finding out suitable reducing agents. The 
most commonly used chemical reducing agents are anhydrous hydrazine [39], 
hydrazine monohydrate [40], sodium borohydrate [41], and hydroquinone [42]. These 
reducing agents are highly toxic, harmful and explosive. Moreover, hydrazine-
reduced graphene tends to agglomerate irreversibly and converts into graphite [43].  
Metal/hydrochloric acid reduction is another alternative, however impurities formed 
from the residual metal hinders further applications [44,45].  
Recently, reduction of GO using environmentally friendly organic agents such as 
vitamin C [46], amino acid [47], glucose [48], protein [49], plant extract [50-52], 
dextran [53], bacterial respiration [54] and E-coli [38] have taken a centre stage and 
have been proposed as alternatives. Although these methods are green, they demand 
lengthy experimental procedures; require expensive reagents and longer reaction 
times. Besides, some of these methods introduce foreign materials to RGO that may 
reduce its purity and limit its further applications. An additional step of sonication is 
often necessary to produce good dispersion in water. Moreover, incomplete reduction 
and formation of large graphene aggregates hamper its good electrical conductivity 
[55]. Most of the reports also claim their suitability for drug delivery; however 
cytotoxicity studies on normal healthy cells have never been looked into. Thus, there  
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is an impending demand to develop an easy approach which can produce RGO with 
good purity but without losing its excellent electrical properties and its 
biocompatibility.  
Ganoderma lucidum (GL) or widely known as Reishi in Japan, or Ling Zhi in China, 
has been a popular mushroom often used in many medicinal applications. It is used in 
the treatment of a variety of ailments such as hypertension, diabetes, hepatitis, cancer 
and AIDS. In Asia and North America, usage of this mushroom extends to 
nutraceuticals and food processing due to many of its astounding properties such as 
anti-oxidant, anti-inflammatory, anti-bacterial, and anti-viral [56-59]. One of the 
interesting properties of this mushroom extract is its high content of polysaccharides 
which exhibit strong anti-oxidant properties [60,61]. Thus, GL extract is a promising 
prospect to be used as a reducing agent in an eco-friendly RGO synthesis. In addition 
to this, the polysaccharide is highly soluble in water and does not react with RGO and 
as a consequence, a simple ultracentifugation step can be carried out to separate the 
reducing agent (extract) after the reaction [28]. From our investigation, it was found 
that the GL extract can be used at least three times with good conversion efficiency 
(75%), as depicted in Figure 2. 
 
 
Figure 2 Schematic representation of RGO production from the reduction of GO. 
 
Following the synthesis of RGO which was found to be highly biocompatible towards 
cancer cells (colon, HT-29 and brain, U87MG) as well as normal (MRC-5) cell lines  
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[28], the possibility of employing RGO as a drug delivery cargo was investigated. 2 
types of hydrophobic drugs were employed, i.e. curcumin (Cur) and Paclitaxel (Ptx) 
in terms of drug loading efficiency, and synergistic effect of these 2 drugs on lung 
(A549) and breast (MDA-MD-231) cancer cells as well as MRC-5 cells were also 
determined.  
Curcumin (Cur) is a yellow colored naturally occurring polyphenolic phytoconstituent 
purified from the rhizome of the plant, Curcuma longa. Cur, despite being well-
known for its anti-inflammatory, anti-oxidant and anti-bacterial properties, it is also 
an anticancer agent which has gained much attention. It was reported to be able to 
suppress and treat various types of malignancies such as breast, cervical, lung, 
prostate, kidney, pancreatic and colorectal epithelial carcinoma [62-66]. This multi-
targeting property is mainly contributed by Cur’s ability to regulate about 100 cell 
signalling pathways [67-69]. Paclitaxel (Ptx), on the other hand is a highly potent and 
toxic anticancer drug isolated from the bark of Taxus brevifolia. Ptx has often been 
studied in various nanoformulations and in conjunction with other chemotherapeutic 
agents to enhance its therapeutic effectiveness. It was reported to be able to inhibit 
breast cancer metastasis [70] and has been used in the treatment of lung, prostate, 
ovarian, and neck carcinomas, however chemoresistance was also observed in some 
instances [71-75].  
Combination drug therapy with the use of Cur and Ptx has proven as an attractive 
anticancer modality [76,77]. In this synergistic treatment approach, the co-delivered 
drug regimen serves as a complimentary effect by targeting different pharmacological 
pathways. At the mechanistic level, Ptx is a potent microtubule-stabilizing agent that 
triggers cell cycle arrest which subsequently leads to cell death via apoptosis [78]. In 
addition to stabilizing microtubules, Ptx up-regulates the expression of nuclear factor-
κB (NFκB) which subsequently leads to the enhanced expression of multidrug 
resistance (MDR) protein, thus promoting cancer cell survival, proliferation, invasion 
and metastasis [79].  On the other hand, Cur attacks biologically by regulating 
multiple signal transduction pathways, including the ability to down-regulate the 
transcriptional factor NFκB, thus eventually inducing cell apoptosis [80]. At the same  
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time, Cur also sensitizes cancer cells so that its response to anticancer drugs increases 
and thus improves the therapeutic potential of Ptx [79,81]. Moreover, Cur also 
overcomes the MDR effect of Ptx by down-regulating the P-glycoprotein production 
and increase the accumulation of Ptx in cancerous cells [82]. By co-delivery, both of 
these drugs enhance caspase-3/7 activity, thus significantly increases apoptosis and 
inhibit lung and breast cancer metastasis [83].  
With the simple functionalization of RGO with an amphiphilic triblock co-polymer, 
such as PF-127 (P), a polymer-functionalized RGO cargo can be produced called GP. 
In GP enhanced stability and solubility can be attained, whereby the polypropylene 
oxide (PPO) groups of the polymer will be adsorbed on the surface of RGO via 
hydrophobic interaction, whereas the polyethylene oxide (PEO) brush will extend out 
imparting solubility [84]. The hydrophobic drugs, Cur and Ptx can then be loaded to 
the empty spaces on the RGO via pi-pi interactions between the drugs and the 
aromatic structures of RGO, as shown in Figure 3.  
 
 
Figure 3 Schematic representation of hydrophobic drugs loaded onto the polymer-
functionalized RGO (GP). 
 
Studies have shown that the drug delivery vehicles that are administered 
intravenously will immediately be cleared from the blood by opsonisation of the 
mononuclear phagocytic system (MPS), also known as reticuloendothelial system 
(RES).  To overcome this, stealth coating of the delivery vehicles with polymers such 
as PEG or pluronic allows extended half-life and blood circulation for more than 40 h 
[85,86]. A pluronic polymer or PEG coated drug delivery vehicle was found to be 
able to significantly increase the level of recirculation and accumulation of drugs in  
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tumor and RES organs. In addition, it was found to have extended presence in the 
systemic circulation at higher concentrations, compared to non-functionalized ones 
[87-89].  
In this engineered design, it is hypothesized that apart from enhanced solubility of Ptx 
and Cur, exceedingly high drug loading on the GP cargo can also be achieved. The 
vast unhindered surface on RGO would allow effective and maximal drug loading via 
pi-pi interactions, which would otherwise be marginally detrimental in GO due to the 
interference of epoxide and hydroxyl functional groups on its surface. Although there 
are many reports on combined drug regimen using Cur and Ptx, the dose tested was 
often random, sometimes in the ratio of 1:1, contradicting the main aim of reducing 
systemic toxicity. An attempt to use the lowest possible amount of Ptx, such as at the 
amount of sub-inhibitory concentration of 20% or sub-effective dose of IC20 along 
with abundance of Cur has never been tested, thus far. In addition, the polymer-
functionalized RGO (GP) cargo is hypothesized to be non-toxic to normal cells and 
thus, this nano-sized material is expected to contribute a better drug delivery into 
cancer cells with increased effectiveness on cancer cell inhibition, compared to 
treatments with single drug agents [90]. 
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2.0 Methodology 
 
2.0 Methodology 
2.1 Materials  
Graphite was purchased from Asbury Graphite Mills, Inc. (Asbury, USA). 
Ganoderma lucidum (commercial grade) was contributed by Ganofarm Sdn. Bhd., 
Malaysia. Typically, mushrooms (including stalk, gills and cap) were dried and 
ground into powder form and sold to the commercial market. Other reagents 
employed were of analytical grade and used as-received. Anhydrous D-Glucose was 
purchased from Fisher Scientific (UK) and PBS buffer was obtained from Sigma 
Aldrich (USA). Ultrapure deionized water was obtained from a Milli-Q Plus system 
(Millipore Corp., USA).  
2.2  Characterization 
The reduction of GO was monitored by measuring the UV-Vis spectrum of the 
reaction at predetermined time intervals using a Lambda 35 Spectrophotometer 
(Perkin Elmer). FTIR spectra of solid samples were recorded on a FTIR Spectrometer 
(Spectrum RX1, Perkin Elmer) in the frequency range of 4000-400 cm
-1
. The 
crystalline nature of synthesized RGO was investigated by using a PANalytical 
X’Pert Pro diffractometer. The XRD was operated at 45 kV with a current of 35 mA 
and using Cu/kα radiation (λ=1.54060). TGA was performed under a nitrogen flow 
(50 mL/min) using a TGA/DSC 1, Star
e
 System (Mettler Toledo). Samples were 
heated from room temperature to 1000°C at 5 °C/min. Ultrasonication was employed 
by using an ultrasonic bath (Elma, Germany, 130 and 35 kHz, 200 W). Zetasizer 
Nano ZS (Malvern Instruments, UK) was used to analyse the hydrodynamic diameter 
of the particles. Samples dispersed in absolute ethanol were drop-casted on Si 
substrate and dried in air before subjecting to Raman and XPS analysis. Raman 
spectra were acquired on a inVia Raman Microscope (Reinshaw) with 514 nm laser 
excitation source. XPS measurements were performed using a Kratos Axis Ultra 
(Shimadzu, Japan) spectrometer equipped with a monochromatized Al kα radiation 
(hv = 1486.6 eV). The graphene/ethanol suspension was also drop-casted on Cu grid  
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(3 nm thick) and mica substrate for HRTEM, AFM and SEM analysis. High-
resolution TEM images were acquired using a Philip model (JOEL, Japan) operating 
at an accelerating voltage of 120 kV. The thickness of graphene materials was 
examined using 5500 Agilent Technologies AFM System (USA) using a nanosensor 
NCH with ultrasharp tips. Morphological analysis was carried out using field 
emission gun SEM (Quanta FEI 400 instrument). 
 
2.3  Preparation of Graphene Oxide (GO) 
GO was produced at room temperature based on the modified Hummer’s method [91]. 
Briefly, to a 3 g of graphite, H2SO4 (95%) and H3PO4 (88%) were added in the ratio 
of 9:1, followed by a slow addition of 18 g of KMnO4. The resulting inhomogeneous 
solution was allowed to stir. After 72 h, the reaction was terminated with the addition 
of 400 g of ice cubes followed by 18 ml of H2O2 (30%). The mixture was then 
centrifuged at 6,000 rpm for 10 min. To the supernatant, 1 M HCl was added to 
discard the sulphate and phosphate ions followed by centrifugation at 11,500 rpm for 
30 min. This was repeated three times followed by washing with DI water for six 
times. The final mixture was a viscous brown GO solution. A standard calibration 
curve of GO was generated by measuring the characteristic absorbance of GO at 230 
nm by using UV-Vis spectrophotometer. The concentration of the prepared GO was 
found to be 10 mg/ml.  
2.4  Preparation of GL extract 
To 1 g of GL mushroom powder, 100 ml of Milli Q water was added and the mixture 
was allowed to boil at 95°C for 3 h. To remove the spent powder, the mixture was 
centrifuged at 10,000 rpm for 15 min. The solution was then stored at 4°C and used 
directly for the reduction of GO as mentioned in section 2.6.  
2.5 Determination of the concentration of GL extract  
Concentration of the GL mushroom extract was determined using the phenol-
sulphuric acid assay [92] with glucose as a reference. Briefly, to a 10 ml of GL 
extract, 30 ml of ethanol was added and stored overnight at 4°C. The crude 
polysaccharide precipitate was then separated by centrifugation at 10,000 rpm for 15  
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min and the clear supernatant was then subjected to vacuum drying at 40°C to obtain 
a solid powder. The powder was then dissolved in 1 ml of Milli Q water and 0.1 ml 
was taken to determine the concentration following the method as reported by [92] 
The concentration obtained was found to be 1 mg/ml.  
2.6  Preparation of RGO using GL extract 
pH adjustments were carried out on the GO solution (0.1 mg/ml) by using NaOH to 
obtain a pH of 7. 50 ml of GL extract was then added to a 50 ml of GO solution and 
transferred to a water bath which was pre-heated to 85°C and allowed to react for 16 h 
at 120 rpm. The resulting black dispersion was then ultracentrifuged at 10,000 rpm for 
20 min to remove the GL extract. The product was then washed three times with 
water to further remove the residual GL extract. The resulting black RGO dispersion 
was then re-dispersed in water. 
2.7 Reusability of GL extract  
The GL extract which was separated in section 2.6 was reused for 2 more cycles to 
reduce the freshly prepared GO using the same reduction protocol. UV-Vis 
measurements were used to determine the amount of GO that was converted to RGO 
by determining the intensity of RGO peak at 260 nm. In each case, the amount of GO 
converted to RGO was calculated. The first use of GL extract was considered as 100% 
conversion from GO to RGO. The yield (%) was determined by drying the obtained 
RGO in an oven for 48 h at 60 °C. 
2.8  GO and RGO size analysis and solubility test 
5 min of ultrasonication (20 kHz, 45% amplitude, 750 W) with a microtip was carried 
out to disperse the GO and RGO before subjecting to size distribution by dynamic 
light scattering (DLS). For solubility test, RGO was dispersed in water, PBS buffer, 
ethanol, methanol and acetone by ultrasonication for 5 min. The dispersed samples 
were kept at RT and observation was continued for 12 months.    
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2.9 Cell lines and culture conditions 
Human grade IV glioblastoma (U87MG), colon adenocarcinoma (HT-29) and normal 
lung fibroblast (MRC-5) cells were used in this study. HT-29 and MRC-5 cells were 
cultured with RPMI (Nacalai Tesque) whilst U87MG cells were cultured with MEM 
containing sodium pyruvate (Nacalai Tesque). The steps on propagation and 
maintenance of the cells were followed as described previously [93].
 
2.10 Neutral red uptake assay 
Cell viability of GO and RGO treatments was performed by neutral red uptake assay 
on U87MG, HT-29 and MRC-5 cells as described by Lim et al. [94]. A total of 5 x 
10
3 
cells were seeded in 96 well plates (SPL Life Sciences, Korea) and incubated 
overnight for attachment. The cells were treated with 200 μl of media containing 0.1-
50 μg/ml of GO and RGO, whereas the cells grown in media without any treatment 
were used as a negative control. Following 48 h of incubation at 37 ˚C, the percentage 
of cell viability was determined. All the experiments were carried out in triplicates in 
three independent experiments. Absorbance readings of the plates were captured by 
using a microplate reader (Thermo Fisher Scientific, USA) at 490 nm. 
2.11 Statistics 
Statistical analysis was performed using the Graphpad Prism (version 5) software. 
One way Anova was used to test for statistical significance between treated and 
untreated groups using Dunnet t-test. Meanwhile, comparison amongst the treatment 
groups was done by two way Anova using Bonferroni t-test. 
2.12 Preparation of GP 
 
PF-127 polymer (P) of 0.12 g were added to 20 ml of G (0.15 mg/ml), followed 
by bath sonication (35 kHz frequency, 100% amplitude, 200 W) for 3 h in a 
pulse mode with 3 min ‘on’ and 15 min ‘off’ to control the temperature which 
was maintained at 25±3 °C. The reaction was then left under a shaker overnight 
at 120 rpm. Subsequently, un-loaded P was removed by dialysis (MW cut-off = 
14 kDa) against double-distilled water and left for a further 24 h. To further  
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remove the unbound polymer, ultracentrifugation at 10,000 rpm for 5 min was 
carried out. The final product, G functionalized with P will be named as GP 
hereafter.  
 
2.13 Cur loading studies 
 
Cur in ethanol (2 ml) of various concentrations (0.1-2 mg/ml) was mixed with 2 ml of 
GP (0.15 mg/ml) and bath sonicated for 1 h, followed by mixing under shaker for 
another 1 h at 120 rpm. The resulting solution was centrifuged at 10,000 rpm for 15 
min. The supernatant was then subjected to UV-Vis analysis, which represents the 
amount of Cur in excess. A Cur in ethanol calibration curve was initially obtained for 
quantification. The Cur loading efficiency is determined as follows, 
 
drug loading capacity = [(Winitial Cur - WCur in excess) / WGP]  x 100 
drug loading efficiency = [(Winitial Cur - WCur in excess) / Winitial Cur] x 100 
 
where, Winitial Cur is the initial weight of Cur added, WCur in excess is the weight of 
Cur in the supernatant and WGP is the weight of GP. Samples were analyzed in 
triplicates. 
 
2.14 Preparation of Cur loaded GP (GP-Cur) and Ptx loaded GP (GP-Ptx)  
 
Synthesis of GP-Cur was based on the maximum loading obtained from the above 
Cur loading studies. Cur (2 mg) was initially dissolved in DMSO/distilled water (1:1) 
solution. GP (0.15 mg/ml) solution was then introduced and the mixture was bath 
sonicated (35 kHz frequency, 100% amplitude, 200 W) for 0.5 h before preparing 
various concentrations of GP-Cur with RPMI media as solvent. For comparison 
purposes, Ptx loaded onto GP (GP-Ptx) was also tested. For GP-Ptx, 1 ml of Ptx in 
DMSO (2 mg/ml) was added to 1 ml of GP (0.15 mg/ml), followed by bath sonication 
for 0.5 h and kept as aliquots at -20°C. Cur and Ptx loaded onto polymer (P-Cur and 
P-Ptx) was also prepared as controls using the same protocol by replacing GP solution 
with the polymer solution.   
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2.15 Preparation of Cur and Ptx co-loaded onto GP (GP-Cur-Ptx)  
 
IC20 of Ptx (determined from the cell proliferation assay, section 2.19) was 
added to the GP-Cur solution, followed by bath sonication (35 kHz frequency, 
100% amplitude, 200 W) for 0.5 h and dilutions as required in RPMI media. 
Briefly, IC20 of Ptx in A549 and MDA cell lines were determined as 69.7 and 
46.7 ng/ml, respectively. Thus 69.7 and 46.7 ng/ml of Ptx were added to GP-
Cur (0.2-200 µg/ml) to be tested against A549 and MDA cells, respectively.  
 
2.16 Cell culture 
 
MRC-5 (human normal lung fibroblast), MDA-MB-231 (MDA, human breast 
adenocarcinoma) and A549 (human lung adenocarcinoma) cell lines were obtained 
from ATCC (Manassas, USA) and cultured in RPMI media supplemented with 10% 
FBS and 1% penicillin/streptomycin. All cell lines were maintained at 37°C in a 
humidified 5% CO2 atmosphere. 
 
2.17 Determination of cell proliferation using neutral red uptake assay 
A total of 5x10
3
 of MRC-5, MDA and A549 cells were cultured in 96-well 
plates, followed by incubation overnight for cell attachment. The cells were 
then exposed to 200 µL of various concentrations of the treatment groups (GP-
Cur, GP-Ptx, GP-Cur-Ptx) and further incubated for 48 h. For comparison 
purposes, unmodified Cur and Ptx were also tested. Briefly, 2 mg/ml of Ptx was 
prepared in DMSO. To obtain the same drug concentration as in GP-Ptx, 1 ml of Ptx 
(2 mg/ml) was added to 1 ml of distilled water. Subsequent dilutions were made in the 
RPMI media. The same protocol was adapted to prepare unmodified Cur. Cells 
grown in the media without any treatment served as a negative control. 
Following 48 h of incubation, the cell viability was determined using the 
neutral red uptake assay according to the previously described protocol [95]. 
The IC50 values were determined using the non-linear regression curve fit of the 
Graphpad Prism5 software. Neutral red was used instead of MTT assay to avoid 
false positive reading as both the drug Cur and MTT solution are yellow-colored,  
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whereas the neutral red is a red-colored reagent that absorbs at a wavelength of 540 
nm in the UV-Vis spectroscopy.  
2.18 Determination of intracellular ROS generation  
 
The generation of intracellular ROS was determined using MAK 142 fluorometric kit 
(Sigma Aldrich, USA). A549 and MDA cell lines were seeded at a density of 5x10
4
 
cells in black 96-well plates with a clear bottom. In a preliminary study, the ROS 
generation peaked at 120 min, which was taken as the incubation time. Cells were 
treated with IC50 and 10-fold IC50 doses of respective treatments (Cur, GP-Cur, Ptx, 
GP-Ptx, GP-Cur-Ptx) and GP (0.15 mg/ml) as well as plain media (untreated) cells 
serving as negative controls. After 120 min of incubation, the ROS generated were 
determined according to the manufacturer’s protocol. Subsequently, the fluorescence 
intensity was quantified using a fluorescence Varioskan flash microplate reader 
(Thermo scientific, USA) with excitation and emission wavelengths fixed at 650 and 
765 nm, respectively. ROS generation was determined as the percentages of ROS 
compared to the control. For fluorescence microscopy imaging, A549 and MDA cell 
lines were seeded in 4-well chamber slides (SPL Life Sciences, South Korea). ROS 
reagents of 125 µL were used and images were captured using Nikon Az100 
fluorescence microscope (Nikon, Japan). 
 
2.19 Determination of MMP depletion  
 
A total of 5x10
4
 A549 and MDA cell lines were seeded in black 96-well plates with a 
clear bottom and were allowed to attach overnight. The cells were then exposed to 
200 µL of the treatment groups at concentrations of IC50, 10-fold IC50 and plain media 
(untreated control) and GP (0.15 mg/ml) to monitor the effect of increased dose. After 
48 h of incubation, MMP in terms of permeability of JC-10 dye was quantified using 
MAK159 MMP kit according to the manufacturer’s protocol (Sigma Aldrich, USA). 
JC-10 forms reversible red-fluorescent aggregates in the healthy cells with polarized 
mitochondrial membrane, however, upon the collapse of MMP, JC-10 returns to its 
monomeric green-fluorescent form [96].
 
MMP loss for each treatment group is  
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calculated as a ratio of green (λex = 490/λem = 525 nm) to red (λex = 540/λem = 590 nm) 
fluorescence and was taken as a percentage over control.  
 
2.20 Determination of apoptosis using Annexin-V assay 
A549 and MDA cell lines were seeded at a density of 5x10
4
 cells in 4-well chamber 
slides and treated with IC50 and 10-fold IC50 doses in comparison with the untreated 
control and GP (0.15 mg/ml) for 24 h. Thereafter, apoptosis was detected using 
Annexin V-Cy3 apoptosis detection kit according to the manufacturer’s protocol 
(Sigma Aldrich, USA) with slight modifications. Briefly, treated cells were washed 
twice with PBS (100 µL) and three times with 100 µL of binding buffer (0.1 M 
HEPES at pH 7.4, 1.4 M NaCl and 25 mM CaCl2). Subsequently, 100 µl of double-
label staining solution containing Annexin Cy-3 and 6- Carboxyfluorescein diacetate 
(6-CFDA) was then added and incubated for 10 min at RT to quantify the living cells 
from apoptotic and necrotic cells. The staining solution was then removed and the 
cells were washed five times with 50 µL of binding buffer. Finally, 50 µL of the 
binding buffer were placed in each well and protected with cover slips and images 
were captured using Nikon Az100 fluorescence microscope fitted with TRITC filter 
(Nikon, Japan). Annexin Cy3 stains red on necrotic cells, by binding to 
phosphatidylserine, which is present outside the plasma membrane of cells 
undergoing apoptosis. Upon entering the living cells, the non-fluorescent 6-CFDA is 
hydrolyzed by esters producing a green-fluorescent product. Cells in the early stages 
of apoptosis, however, stained yellowish-green [97].
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3.0 Results and Discussion 
 
3.1 Characterizations of RGO 
The reduction of GO using GL extract was monitored by time-dependent UV-Vis 
spectroscopy as shown in Figure 4. The strong absorption peak at 230 nm (0 h) is a 
distinctive peak of GO which corresponds to π-π* transition of C=C bond and the 
shoulder at 300 nm is due to n-π* transition of the C=O bonds in GO. Gradual red-
shifting of the 230 nm peak towards 260 nm can be seen during the reaction, 
suggesting the restoration of π-conjugation network of RGO after reduction. 
Moreover, the gradual disappearance of the plasmon peak at 300 nm confirms the 
removal of oxygen groups in RGO [30,98,99]. The formation of RGO was observed 
within 1 h with the red shift of a typical GO peak at 230 nm to 251 nm. The highest 
absorbance was observed at 16 h, which indicates that reaction time is directly 
proportional to the amount of RGO formed. A tested duration of 48 h gives ≈73% 
yield. 
 
 
Figure 4 UV-Vis spectra of GO reduction with GL extract at different time intervals. 
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The formation of RGO is further confirmed by FTIR spectroscopy as shown in Figure 
5a. FTIR spectra of GO shows a strong absorption peak of νO-H at 3412 cm
-1
 due to 
stretching vibrations and a deformation peak at 1396 cm
-1 
due to the hydroxyl groups 
located on the plane of GO. Carboxyl groups at the edges of GO sheets show 
stretching vibration and the νC=O peak appears at 1726 cm
-1
. The spectra also exhibit 
several characteristic peaks of GO; νC=C at 1630 cm
-1
 due to the aromatic C=C bonds;  
νC-O at 1246 cm
-1
 due to the epoxy C-O stretching vibration; and  νC-O at 1116 cm
-1
 
due to the alkoxy C-O stretching vibration [31,38,100]. Compared to graphite the GO 
spectrum indicates successful oxidation with the presence of hydroxyl, epoxy, alkoxy 
and carboxyl functional groups. Successful deoxygenation could be seen for RGO 
with the disappearance and reduced intensities of all the oxide functional groups. A 
broad C-O band that appears from 1214 to 1000 cm
-1 
even after reduction could be 
attributed to oxygen atoms or cyclic ether accumulated at the edges of defects in 
RGO. This indicates that all the oxygen groups are removed from the region adjacent 
to edges and only clean graphene domains are present in RGO [4,101]. The spectra of 
GL extract exhibit a broad band around 3397 cm
-1
 due to the stretching of N-H and O-
H groups, and a corresponding N-H bending at 1639.5 cm
-1
. Other characteristic 
peaks of the GL extract are at 2930 cm
-1
 and at 2884.9 cm
-1
 due to the asymmetric 
stretching of CH3 and symmetric stretching of CH2, respectively. The sharp peaks at 
1074.4 cm
-1
 and at 1046.5 cm
-1
 are due to C-O stretching and bending of C-OH in the 
polysaccharide [102,103]. The absence of these characteristic peaks in RGO confirms 
the complete removal of the GL extract after the reaction. 
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Figure 5 (a) FTIR spectra of (i) graphite, (ii) GO, (iii) RGO and (iv) GL extract; (b) 
XRD patterns of (i) graphite, (ii) GO and (iii) RGO. 
 
 
The XRD analysis (Figure 5b) is a good tool to estimate the interlayer spacing 
between the graphitic layers, the crystalline properties as well as to determine the 
completion of reaction. Graphite exhibits a strong basal reflection (002) at 2θ = 26.6° 
with an interlayer distance (d-spacing) of approximately 0.33 nm. This intense 
crystalline peak is a characteristic peak of hexagonal pristine graphite. The 
disappearance of this peak in GO confirms the complete oxidation of graphite. Upon 
oxidation, the diffraction peak (001) of GO appears at a lower angle (2θ = 9.2°) with a 
d-spacing of 0.96 nm. The larger interlayer spacing after oxidation is due to the 
intercalation of oxide functional groups on both sides of GO sheets. In addition, 
structural defects (sp
3
 bonding) generated on the originally flat graphite sheets 
contribute to an atomic-scale roughness and thus a larger d-spacing of GO [104]. 
After reduction, the distinctive GO peak of RGO disappears indicating reduction as 
well as exfoliation of the layered RGO sheets [49,105]. A broad peak has been 
observed for RGO, starting from 2θ = 15 to 30°, with the peak centred at 2θ = 24.0°, 
and a d-spacing of 0.37 nm. The appearance of this peak at 24.0° is due to restoration 
of van der Waals interaction between the carbon frameworks on the graphene sheets  
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upon reduction. The presence of a broad peak indicates the loss of a long range order 
in the graphene sheets and stacked with few layers thickness [43,100,106,107]. In 
addition, the significant reduction in the interlayer spacing of RGO as compared to 
GO suggests the removal of oxygen groups and water molecules from the interlayer of 
graphene sheets in RGO.  
The formation of RGO was further confirmed by XPS analysis. The C1s of GO as 
shown in Figure 6a demonstrates the highest intensity at the binding energy of 287.8 
eV, which belongs to carbonyl functional groups. Other peaks at 284.8, 286.3 and 
289.1 eV correspond to C=C/C-C in aromatic rings; C-O in hydroxyl and epoxy 
groups; and O-C=O in carboxyl groups, respectively [38,43,108]. After reduction, the 
peak intensity for all the oxygen species has decreased dramatically suggesting the 
effective removal of oxygen containing groups in RGO. In addition, a sharp increase 
in the C=C/C-C peak at 284.4 eV and the appearance of a pi-pi* peak at 288.5 eV 
indicate the restoration of sp
2
 carbon network [109]. C/O molar ratio calculated from 
the peak areas shows a very high content of oxygen species in GO (1:13.6), whereas 
in RGO the molar ratio was found to be only 1:2.16, again confirming the successful 
reduction of GO.       
 
Figure 6 XPS spectra of C1s of (a) GO and (b) RGO. 
 
Figure 7 shows the FESEM images of GO and RGO. It could be observed that GO 
(Figure 7a) has a continuous and smooth wave-like sheets, whereas a flake-like 
morphology could be noted in RGO (Figure 7b) which forms a disordered solid with  
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the individual sheets closely stacked [110,111]. With the removal of oxygen groups 
from the basal plane as well as from the edges of RGO, the graphene sheets are now 
allowed to closely associate and stack via van der Waals interactions. This finding is 
in good agreement with the results of XRD obtained for RGO, where the d-spacing or 
interlayer distance is smaller than GO, permitting the stacking of RGO flakes. The 
RGO flakes lie flat on top of each other suggesting the possibility of good electrical 
contact between them [112]. The microstructure of GO and RGO was further 
investigated by HRTEM. It could be seen that GO has a wavy structure with few well-
defined layers of stacking at the edges (Figure 7c). The observed stacking could be 
due to strong hydrogen bonding interaction between the GO layers or with water 
molecules [113]. As for RGO, thin veil-like sheets were observed with scrolling and 
wrinkles which confirms that the reduction of GO has taken place. It was reported that 
scrolling is caused by the presence of isolated epoxy and hydroxyl groups, whereas 
the wrinkles are due to the removal of strain on the C-C bond in the epoxy groups 
which was created during the formation of three-membered epoxide ring in GO [114]. 
In addition, RGO appeared transparent which is similar to the graphene produced 
from electrolytic exfoliation of graphite.  Lateral dimension of RGO in both FESEM 
and HRTEM was approximately 500 nm. 
To further confirm the reduction of GO, Raman spectroscopy was used to investigate 
the nature of layering and defects on the graphitic sheets. The Raman spectra of 
graphite (Figure 8) displays a sharp G band at 1582 cm
-1
 due to in-phase vibration of 
the graphite lattice and a weak D band at 1370 cm
-1
 indicating low degree of defects 
that are mostly due to the sheet edges. In comparison, GO exhibits a prominent G 
band which is blue-shifted to 1586 cm
-1
 signifying the presence of isolated double 
bonds which resonate at higher frequencies than that of graphite. The intensity of D 
band at 1352 cm
-1
 was also increased which could be attributed to the decrease in size 
of in-plane sp
2
 domains compared to graphite [38,43,49,104]. For RGO, the G band is 
broadened and shifted to 1611 cm
-1
 and moved closer to the G band of graphite 
attributed to graphitic self-healing and successful reduction [115], as the removal of 
oxygen groups allows the RGO to associate and re-stack. The D-band of RGO  
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becomes more prominent and remains almost at the same position as GO i.e. at 1351 
cm
-1
.  
                                                                                                                                                                                                                                                        
Figure 7 FESEM images of (a) GO and (b) RGO and HRTEM images of (c) GO and 
(d) RGO. 
 
The intensity ratio of D to G (ID/IG) is a good indicator of the degree of distortion in 
the graphitic sheets. As expected, the intensity ratio of RGO has dramatically 
increased to 0.99 as compared to GO (0.94) and graphite (0.07). A higher intensity 
ratio as seen in GO compared to graphite is due to the introduction of defects after 
oxidation of graphite, whereas the highest intensity ratio seen in RGO indicates 
disorder on the graphene sheets after reduction and an increase in the number of sp
2
 
domain. It is suggested that the reduction of GO causes fragmentation and yields 
smaller RGO graphitic domains with different sizes [116,117].   
The 2D band represents the symmetry-allowed overtone of the G band. The shift, 
shape and width of the 2D peak are sensitive to the stacking order of the graphene  
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sheets along the c-axis and the number of graphene layers, in which single-layered 
graphene has a single sharp Lorentzian peak below 2700 cm
-1
. Multiple layered sheets 
have broader and up-shifted 2D peaks [30,100,104,118]. The broad 2D band of 
graphite from 2627 to 2776 cm
-1
 indicates the presence of multiple layered graphite 
sheets, whereas the 2D band of GO at 2700 cm
-1
 indicates a single layered sheet. After 
reduction, this peak has marginally broadened and shifted to 2769 cm
-1
 suggesting the 
presence of three-layered graphene sheets [119]. The cooperation between D and G 
peaks gives    D + G combination band which indicates the presence of highly 
disordered and randomly arranged graphene sheets [30,31]. The D + G band is 
observed for GO at 2690 cm
-1
 and a slightly broader band is observed for RGO at 
2692 cm
-1
 indicating the presence of more random arrangement in RGO. The absence 
of these peaks in graphite shows that it exists as a continuous long sheet. 
 
Figure 8 Raman spectra of (a) graphite, (b) GO and (c) RGO. 
 
GO and RGO were then subjected to AFM to determine their respective topography 
as well as thickness (Figure 9). The cross-section from AFM analysis shows that the 
maximum thickness of GO is approximately 1 nm which is in compliance with the d-
spacing of GO i.e. 0.96 nm as determined by XRD. After reduction, the RGO’s 
thickness is approximately 1-2 nm. The thickness obtained is similar to those  
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produced from hydrazine reduced GO [120,121] and hydrothermally reduced GO 
[114].  
 
Figure 9 AFM images of (A) GO and (B) RGO with respective thickness 
measurements taken along the cross-section, as indicated by a line and a red arrow. 
 
Based on the XRD analysis of RGO with 0.37 nm d-spacing, it could be estimated 
that RGO is few-layered (3-5 layers) similar to the observation made using Raman 
analysis.  
The particle size distribution of aqueous dispersion of GO and RGO was determined 
by DLS analysis. Although DLS is more suitable for spherical particles rather than for 
planar sheets like graphene, it serves to indicate whether a uniformly-sized dispersion 
of graphene was produced in addition to demonstrating the changes in the size of GO 
and RGO. As shown in Figure 10, the average size of GO and RGO is 313 nm and 
181 nm, respectively. In GO, the peak appearing after 1,000 nm could be due to the 
presence of remnants from the reaction of graphite oxidation. Also, the presence of 
undisrupted long continuous sheets in the GO results in larger size. RGO however 
shows a uniform size distribution with sizes generally at least two times smaller than  
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GO. This concludes that there is a loss of long range graphitic order in RGO and 
corroborates with the observation of a D+G peak in the XRD spectra. The smaller 
sized RGO observed could be mainly due to the method of synthesis employed and 
due to the effect of 5 min of ultrasonication. Generally, ultrasonication breaks the 
RGO nanosheets to smaller fragments, a similar observation was also noted in GO 
[122]. In addition, ultrasonication of RGO results in better dispersion in water. A 
solubility test conducted (Figure 10) shows that RGO is stable in the tested solvents 
for up to 12 months, without any visible aggregation or sedimentation. It is reported 
that ultrasonic treatment induces cavitation near surfaces of RGO sheets which 
inhibits the aggregation of RGO by weakening its van der Waals interactions and thus 
enhanced the formation of stable RGO dispersion [109].  
 
 
Figure 10 Above: Size distribution analysis on a) GO and b) RGO with its respective 
polydispersity index (PDI) and average size (Z). Below: Solubility of RGO in (a) 
water (b) PBS buffer (c) ethanol (d) methanol and (e) acetone. 
 
3.2 Cell viability of GO and RGO on normal and cancer cells 
Based on the fact that viable cells incorporate and bind more dye as compared to 
damaged or dead cells [123], the dose dependent cytotoxicity of GO and RGO can be 
determined by neutral red uptake assay. Cell viabilities were normalized using  
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untreated cell readings. Both GO and RGO showed no significant toxicity towards 
HT-29 cells as shown in Figure 11a. Over 90% cell confluence was observed at the 
highest concentration (50 µg/ml), even for GO. However, a different cytotoxicity 
pattern is seen in U87MG cells as shown in Figure 11b. A decrease in cell viability 
was observed for GO starting from 10 µg/ml when compared to untreated cells. GO 
has been largely reported to cause plasma membrane damage and oxidative stress, 
thus the anti-proliferative distress to the cells [124]. On the other hand, RGO was 
found to be biocompatible with almost 100% cell confluency even at the highest 
concentration (50 µg/ml). By comparing GO with RGO, significant difference in cell 
viability was observed starting from the concentration of 25 µg/ml (p < 0.01).  
 
 
Figure 11 The cell viability (%) on (a) HT-29, (b) U87MG and (c) MRC-5 cells and 
(d) overall IC50 values of GO and RGO treatments for 48 h generated by neutral red 
uptake assay. Bars represent mean±SEM of triplicates in three independent 
experiments (n=9). (*) = significant difference when treated groups were compared 
with untreated (p < 0.001) using one way Anova with Dunnel t-test. (#,##) = 
significant difference when GO was compared to RGO with p < 0.5 and p < 0.01, 
respectively, using two way Anova with Bonferroni t-test.  
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GO (Figure 11c) shows obvious toxicity towards MRC-5 as compared to the un-
treated cells even from concentration as low as 5 µg/ml as GO was reported to induce 
cytotoxicity, genotoxicity and oxidative stress to MRC-5 cells. In contrast, RGO 
showed no cytotoxicity towards normal cell lines with the cell viability above 90%, 
even at 50 µg/ml.  
GO was found to be toxic especially towards U87MG cells with IC50 at a very low 
concentration of 26.27 µg/ml (Figure 11d). This is due to the presence of oxygen 
functional groups in GO, which consequently lead to oxidative stress to cells and 
results in poor cell survival [99]. RGO shows better cell survival compared to GO for 
all the three cell lines with IC50 values beyond 50 µg/ml and up to 390 µg/ml. Since 
the cell viability assay is conducted only up to a concentration of 50 µg/ml, the 
concentration values in Fig. 9d only serve as an estimation generated by the software. 
Nevertheless, based on the current findings, our mushroom synthesized RGO, without 
the need of any functionalization shows good aqueous stability and is equally 
biocompatible similar to the functionalized ones such as carboxyl modified graphene 
[125].  Although our RGO does not pose any selectivity against the two cancer cell 
lines and normal cells tested, this feature is still of great value for the synthesized 
RGO to be a tool for protein/gene transfection as well as a drug delivery vehicle for 
cancer treatment, such as by the conjugation of an anticancer drug, as reported in 
subsequent section.     
 
3.3 Charaterizations of polymer-functionalization of RGO forming a GP cargo 
The successful functionalization of RGO with polymer was further validated using 
XRD (Figure 12a). The semicrystalline polymer, P, has two peaks at the same region 
of RGO starting at ≈19-36° [126,127]. Upon functionalization, these peaks appeared 
in the GP composite with an overlap of RGO and P bands at 15-19°. The peaks also 
appeared red-shifted compared to RGO and P alone, revealing successful 
functionalization. 
 
Extended abstract        
K. Muthoosamy   
 
27 
 
 
The thermal stability of GP was analyzed by TGA as shown in Figure 12b. P suffered 
from 100% weight loss, with obvious weight drop seen from 270-400°C, which is due 
to the decomposition of the PEO and PPO copolymer [128]. However, upon 
functionalization with RGO, GP showed enhanced thermal stability.  
 
 
Figure 12 (a) XRD patters of RGO, P and GP. (b) TGA curves of RGO, P and the 
functionalized GP. Note: RGO: reduced graphene oxide; P: polymer; GP: polymer-
functionalized reduced graphene oxide. 
 
3.4 Characterizations of Cur and Ptx loaded onto GP 
Upon modification of RGO with P resulting in GP, surface roughness was created 
with the presence of a porous structure, as shown in Figure 13b. In addition, the 
height profile shows increased thickness of ≈4 nm, which is due to the immobilization 
of P onto the surface of RGO. Accordingly, the height profile of GP-Cur is around 2 
nm and upon introduction of Ptx has increased by ≈2-3 nm, confirming the non-
covalent interaction of Cur and Ptx on the surface of GP. In addition, it is presumed 
that the molecules of Cur and Ptx, which are smaller in sizes, could have filled the 
pores that appear in GP.   
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Figure 13 Tapping mode AFM images and its corresponding height profiles for (a) 
RGO, (b) GP, (c) GP-Cur and (d) GP-Cur-Ptx. Note: RGO: reduced graphene oxide; 
GP: polymer-functionalized reduced graphene oxide; GP-Cur: curcumin loaded onto 
GP; GP-Cur-Ptx: curcumin and paclitaxel co-loaded onto GP. 
 
The hydrophobic interaction between Cur and the cargo GP can be further ascertained 
in fluorescence emissions (Fig. S1). Graphitic materials generally induce quenching 
upon interaction with aromatic or double bond conjugated materials, which is an  
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imperative tool to confirm loading of the fluorescent materials or drugs. At 420 nm 
excitation wavelength, Cur exhibited maximum fluorescence emission at   ≈540 nm.  
In GP-Cur however, a 93% quenching of fluorescence was observed which is due to 
the strong pi-pi interaction between the conjugated system in Cur and the aromatic 
structures in GP. As a result, a photoinduced electron-transfer process or fluorescence 
resonance energy transfer (FRET) takes place in the GP-Cur hybrid system that 
diminishes fluorescence [84,129,130]. Interestingly, the fluorescence signal was 
found higher (78% quenching) upon introduction of Ptx to the GP-Cur system. This 
phenomenon may be ascribed to the loading of Ptx molecules which interferes with 
the GP-Cur interaction, consequently releasing Cur from GP, which then exhibits 
increased fluorescence intensity [21]. In comparison, GP, Ptx and GP-Ptx did not 
demonstrate any fluorescence activity.  
The surface morphology of the materials can be further elucidated using FESEM. As 
reported above, RGO has a flake-like structure with closely packed graphene sheets 
[28]. After functionalization with P, the GP has obvious surface roughness (Figure 
14a) and with higher magnification, the microporous structure was observed, which is 
consistent with the topographical observation under AFM (Figure 14b). On the 
contrary, in the hybrid system, crystals of Cur in either rectangular or cubic shapes 
appeared to decorate the surface of GP, which is also in line with the observations 
reported in other studies [131,132]. Similarly, the appearance of granule like Ptx in 
the GP-Ptx hybrid system confirms the successful pi-pi interaction of Ptx and the GP. 
In GP-Cur-Ptx, more homogenous and non-aggregated drug loading was observed. 
Under higher magnification, the spherical structure of polymers can be seen adsorbed 
on the surface of G, together with the drugs which appeared brighter under the 
FESEM.  
The lateral and size distribution of the aqueous dispersions of drug loaded GP were 
evaluated further using DLS. Upon modification with P, the size of GP slightly 
increased owing to the adsorption of polymer onto the flat surface of the RGO (Table 
1). In their unmodified form, Cur and Ptx dissolved in ethanol/water (1:1) have  
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average sizes much larger than their hybrid form of GP-Cur and GP-Ptx, respectively. 
As both are hydrophobic drugs, the aqueous dispersion is somehow limited, however 
upon loading onto GP, the solubility of these drugs were significantly improved thus 
the lowered average sizes. A more convincing result can be seen in GP-Cur-Ptx, 
whereby upon loading of the drugs, the hydrodynamic average size was increased to 
≈140 nm, which is higher than GP-Cur and GP-Ptx, proving the co-loading of Cur and 
Ptx onto the GP cargo system.  
The size of the drug loaded GP carrier which is below 200 nm is highly advantageous 
for drug delivery applications as drug carriers within these sizes have been shown to 
have long half-life in the blood [133,314]. Since the tumor vasculature have defective 
architecture within these pore sizes, consequently this increases the propensity of the 
drugs to extravasate through vascular fenestrations of tumors and escape filtration by 
liver and spleen [86,135]. In addition, the poor lymphatic drainage of tumor cells 
prevents an efficient removal of the drug carrier and collectively <200 nm drug carrier 
allows enhanced permeability and retention (EPR) effect, which increases the drug’s 
efficacy [136].   
 
3.5 Drug loading studies of Cur onto GP cargo 
From the various concentrations of Cur tested (0.1-2 mg/ml), the highest amount of 
Cur loading was 2 mg with the loading efficiency of ≈97% and loading capacity of 
678 wt. %. Loading efficiency is determined as a percentage of experimental drug 
loading compared to theoretical drug loading, whereas loading capacity is determined 
as weight of the drug loaded compared to the weight of the GP cargo. As described 
earlier, this remarkably higher drug loading is mainly due to the unperturbed surface 
that is present on GP, contributing to efficient pi-pi interaction with Cur molecules. 
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Figure 14 FESEM images of (a) GP, (b) GP in higher magnification, (c) GP-Cur,         
(d) GP-Ptx, (e) GP-Cur-Ptx and (f) GP-Cur-Ptx in higher magnification.  
Note: GP: polymer-functionalized reduced graphene oxide; Cur: curcumin; GP-Cur: 
Cur loaded onto GP; Ptx: paclitaxel; GP-Ptx: Ptx loaded onto GP; GP-Cur-Ptx: Cur 
and Ptx co-loaded onto GP. 
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Table 1 
The average hydrodynamic diameter of GP and drug loaded GP and its respective 
polydispersity index (PDI). 
Sample Average 
size (nm) 
PDI 
GP 156.3 0.111 
Cur 231.6 0.019 
Ptx 148.0 0.038 
GP-Cur 123.5 0.245 
GP-Ptx 133.1 0.078 
GP-Cur-Ptx 139.9 0.063 
 
Note: GP: polymer-functionalized reduced graphene oxide; Cur: curcumin; GP-Cur: 
Cur loaded onto GP; Ptx: paclitaxel; GP-Ptx: Ptx loaded onto GP; GP-Cur-Ptx: Cur 
and Ptx co-loaded onto GP. 
 
3.6 Cytotoxicity assessment of GP-Cur-Ptx against A549, MDA and MRC-5 cells  
Following cell viability studies, the antiproliferative effects of Cur and Cur loaded 
onto GP (GP-Cur) against A549 and MDA cell lines were determined. A dose-
dependent cell viability was observed with cell growth inhibition evident at 0.2 µg/ml 
of GP-Cur in A549 and 20 µg/ml for MDA cells (Figure 15a, b). A similar dose-
dependent pattern was also observed upon treatment with Ptx and GP-Ptx. Significant 
growth inhibition was evident at 20 ng/ml in cells treated with GP-Ptx, in contrast to 
90% cell viability observed in cells treated with same concentration of Ptx alone 
(Figure 15c, d). As shown in Table 2, Ptx induced 50% growth inhibition in A549 and 
MDA cell lines with IC50 values of ≈0.17 and ≈0.12 µg/ml, respectively. Remarkably, 
an IC50 value of 0.0077 µg/ml of GP-Ptx was observed against A549 cells 
representing almost 25-fold reduction in the required potent dose as compared to Ptx. 
Similarly, only 0.0148 µg/ml GP-Ptx was needed to achieve IC50 in MDA cells, which 
is 8-fold lesser amount than using Ptx alone.   
Since pluronic polymer has been suspected to be able to improve the cellular uptake 
of drugs, Cur and Ptx loaded polymer (P-Cur and P-Ptx) were also taken as controls 
(Figure 15A-D). Based on the observations, the cytotoxicity of P-Cur and P-Ptx 
appears to be the same as Cur and Ptx, respectively. This concludes that in the drug  
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loaded polymer solutions, the drugs present as a mixture rather than forming micelles 
with the pluronic polymer. If the latter was formed, higher cytotoxic effect will 
otherwise be observed as compared to Cur/Ptx.  
Pluronic polymers alone cannot be considered as an optimal delivery vehicle for the 
hydrophobic drugs due to their low solubility in aqueous media and short residence 
time in the physiological environment [137]. Thus, alterations such as polymeric 
micelles, covalent modifications or polymer thermogels based synthesis are necessary 
to encapsulate the hydrophobic drugs (Cur/Ptx). In this work, the drugs (Cur/Ptx) 
were loaded via simple mixing and bath sonication for 0.5 h, which is believed to be 
not sufficient to form micelle or covalent bond or thermogels with the residual 
pluronic polymer, if any. A similar finding was also previously reported [138], 
whereby a non-covalent functionalized pluronic polymer-CNTs showed no 
enhancement in the cellular uptake by A549 cells as compared to covalent 
functionalized ones. 
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Figure 15: Representative histograms showing dose dependent growth 
inhibition of A) A549 cells treated with Cur, P-Cur and GP-Cur, B) MDA cells 
treated with Cur, P-Cur and GP-Cur, C) A549 cells treated with Ptx, P-Ptx and 
GP-Ptx, D) MDA cells treated with Ptx, P-Ptx and GP-Ptx, E) A549 cells 
treated with GP and GP-Cur-Ptx and F) MDA cells treated with GP and GP-
Cur-Ptx. Following 48 h of treatment, IC50 was determined as described in the 
methods. Bars represent the mean ± SEM of triplicates from three independent 
experiments (n=9). *, ** and *** indicate significant difference when 
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compared between treatment groups, with P<0.5, P<0.01 and P<0.001, 
respectively using two-way ANOVA with Bonferroni t-test.  
 
 
The enhanced cell toxicity effects seen in GP-Cur and GP-Ptx hybrid system could be 
due to better solubilisation of these drugs, upon loading onto the GP cargo system. 
The synthesized RGO [28], has good dispersion and stability in both water and 
physiological solution, which could have contributed to better solubilisation of the 
loaded drugs. In addition to this, the high surface area coverage on RGO allows more 
reactive sites of the drugs available for cytotoxicity reaction to take place and possibly 
better cell internalization. These findings raise the concern whether the markedly 
increased cellular toxicity of the GP-Cur and GP-Ptx hybrid system was due to 
toxicity from GP, instead of the drugs. Cell viability studies showed that GP did not 
induce toxicity to A549 and MDA cell lines, even at high concentration of 200 µg/ml 
(Figure 15e, f).  
Based on the cell viability assay, the IC20 of Ptx was determined as 69.7 ng/ml for 
A549 cells and 46.7 ng/ml for MDA cells. With the introduction of 69.7 and 46.7 
ng/ml of Ptx onto GP-Cur to the A549 and MDA cell lines, respectively, inhibition of 
cell growth was observed at 0.2 µg/ml (Figure 15e, f). IC50 values showed that the 
GP-Cur-Ptx system was slightly more potent towards MDA cells, needing only 1.450 
µg/ml drugs, compared to 13.24 µg/ml for A549 cells (Table 3).  The combination 
index (CI) calculated based on previously described method [139],  showed 
synergistic growth inhibition by Ptx loaded GP-Cur (GP-Cur-Ptx) against the tested 
cells with slightly higher potency observed in MDA (0.43) compared to  A549 (0.54) 
cells (Table 3). 
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Table 2 
The 50% inhibitory concentration (IC50) values of Cur and Ptx; Cur and Ptx loaded 
onto GP (GP-Cur and GP-Ptx) and Cur and Ptx co-loaded onto GP (GP-Cur-Ptx), 
tested against A549 and MDA cell lines. 
 
 
 
 
Note: Cur: curcumin; GP: polymer-functionalized reduced graphene oxide; GP-Cur: 
curcumin loaded onto GP; Ptx: paclitaxel; GP-Ptx: Ptx loaded onto GP.  
 
 
Table 3 
Combination index (CI) analysis of GP-Cur-Ptx against A549 and MDA cell lines and 
the effects of these doses on MRC-5 cells, in terms of IC50 values.  
 
Note: Pharmacological interaction deduced the CI values of >1 as antagonistic, =1 as 
addictive and <1 as synergistic.  
 
 
In order to ascertain that the synergistic system is not toxic towards healthy cells, 
cytotoxicity test was also conducted against MRC-5 cells. As shown in Table 2, GP, 
Cur and combined GP-Cur did not cause toxicity to non-cancerous MRC-5 cells. 
However, Ptx and GP-Ptx caused toxicity at 400-500 ng/ml. On the other hand, 25.71 
µg/ml of GP-Cur in combination with IC20 (69.7 ng/ml) of Ptx was required to induce 
50% growth inhibition in MRC-5 cells compared to 13.24 µg/ml required for the 
cancerous A549 cells (Table 3). Similarly, 37.50 µg/ml of GP-Cur was required in  
Treatment 
(µg/ml) 
A549 MDA-MB-231 MRC-5 
Cur  17.83 ± 1.4 49.42 ± 1.3 > 200 
GP-Cur  96.13 ± 1.1 42.98 ± 1.4 > 200 
Ptx  0.1743 ± 0.0013 0.1174 ± 0.0016 0.5237 ± 0.0014 
GP-Ptx  0.0077 ± 0.0015 0.0148 ± 0.0016 0.4041 ± 0.0012 
GP  > 200 > 200 > 200 
S/no Cells IC20 doses of 
Ptx (ng/ml) 
Doses of GP-Cur that induced 50% 
growth inhibition in combination 
with IC20 dose of Ptx (µg/ml) 
CI 
1 A549 69.7 13.24 ± 1.8 0.54 
2 MDA 46.7 1.450 ± 1.9 0.43 
3 MRC-5 69.7 25.71 ± 1.2 - 
4 MRC-5 46.7 37.50 ± 1.2 - 
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combination with 46.7 ng/ml Ptx to induce 50% growth inhibition in MRC-5 cells 
compared to 1.450 µg/ml of GP-Cur required for MDA cells. This demonstrated that 
combined treatment conferred less toxicity on non-cancerous MRC-5 cells compared 
to A549 and MDA cell lines. 
 
3.7 Determination of ROS generation by GP-Cur-Ptx in A549 and MDA cells 
The cytotoxicity of the agents towards the cancer cells was further confirmed with 
determination of oxidative stress by a fluorometric assay. Upon incubation with cells, 
the generated ROS reacts with the fluorogenic component localized in the cytoplasm, 
resulting in red-fluorescent product, which is proportional to the amount of ROS 
present. 
In both of the cancerous cells, 10-fold GP-Cur-Ptx exuberantly elevated oxidative 
stress in the intracellular environment in a dose-dependent manner (Figure 16a, b). In 
case of A549 cells, by comparing all the 10-fold IC50 treatment groups, 10-fold Cur 
demonstrated the second highest ROS elevation followed by 10-fold GP-Cur, which 
suggests that the presence of a higher concentration of Cur has contributed to the 
amplified production of ROS. In addition, by comparing the hybrid systems i.e.     
GP-Cur and GP-Ptx, GP-Cur showed a significantly higher generation of ROS. It was 
reported that Cur could either potentiate the accumulation of ROS or stimulate the 
generation of ROS by other anticancer drugs [140]. Although Cur possesses good 
ROS scavenging ability, in the GP-Cur hybrid system, Cur acts as a pro-oxidant by 
bringing cellular redox changes resulting in the accumulation of ROS which 
consequently lead to cell death [141-143]. On the contrary, Ptx, is reported to induce 
only a small amount of ROS due to the presence of a negative regulator of a 
mitochondrial ROS called UCP-2 [144]. Hence, in the synergistic GP-Cur-Ptx system, 
Cur acts as an antioxidant which may have an adverse effect on the anticancer drug 
Ptx, which then acts on tumor cells by increasing the ROS level to induce cell death 
[145,146]. The findings of considerably higher ROS values as observed in the GP-
Cur-Ptx corroborate well with the highest cell killing in the previous cytotoxicity 
assay which indicates that the presence of both Cur and Ptx have effectively induced  
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toxicity to cancerous cells probably via a supplementary ROS-mediated mechanism. 
The significantly higher ROS generation as observed in MDA than in A549 cells, 
which substantiates with the higher potency of GP-Cur-Ptx for MDA as seen in 
cytotoxicity assay indicates the vulnerability of MDA to ROS assaults.   
Figure 17 shows the ROS images of GP-Cur-Ptx on A549 and MDA cells. The 
brighter red-fluorescence shows higher ROS generation and accumulation as 
compared to unstained images of un-treated cells as well as lightly stained cells 
observed in       GP-Cur and GP-Ptx (Fig. S2). The rod-like structure seen outside the 
cells shows the presence of GP which serves as a drug delivery vehicle and it 
corroborates with the hypothesis that only drugs were internalized by cells, leaving 
behind the GP cargo. 
The shape of the drug carrier which is rod-like is also advantageous for drug delivery 
as rod-like drug carriers are found to exhibit 4-times more rapid transvascular 
penetration [147]. This was observed mainly due to reduced steric hindrance with 
high aspect ratios and minimal regions of curvature with its worm-like particle or 
structure [148]. In addition, these rod-like structure of drug carriers is also reported to 
posses optimal transport properties as the rod-like drug carrier has long-circulating 
lifetimes compared with the spherical ones due to their tendency to align with blood 
flow [149-151]. 
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Figure 16 Percentages of ROS generation, loss of MMP and apoptosis. (A) Activity 
of ROS generation by the treatment groups on A549 and (B) MDA cell lines. (C) The 
loss of mitochondrial membrane potential (MMP) induced by treatment groups on 
A549 and (D) MDA cell lines. (E) Percentage of apoptosis induced by the treatment 
groups on A549 and (F) MDA cell lines. Plain media and GP served as untreated 
control (Ut) and negative control, respectively. Concentrations of the treatment groups 
are based on the respective IC50 and 10-fold IC50 values. Bars represent mean ± SEM, 
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with n=3. *, ** and *** indicate significant difference when treated groups were 
compared with un-treated with P<0.5, P<0.01 and P<0.001, respectively using one-
way ANOVA with Dunnett’s t-test.  
 
 
Figure 17 Representative images of ROS generation in (A) A549 and (B) MDA cell 
lines after treatment with GP-Cur-Ptx for 120 min. Arrows indicate the rod-like 
structure as seen outside the cells, which are the GP cargo. Note: GP-Cur-Ptx: 
curcumin and paclitaxel co-loaded onto GP. 
 
3.8 Determination on the degree of MMP loss in A549 and MDA cells 
ROS assault on cells is often accompanied by mitochondrial malfunction, or 
sometimes both happening concurrently. Thus MMP was investigated on both A549 
and MDA cancer cells at the concentrations of IC50 and 10-fold IC50. JC-10, a 
cationic, lipophilic dye was used to monitor the MMP in term of permeability to JC-
10 quantitatively. JC-10 forms reversible red-fluorescent aggregates in healthy cells 
with polarized mitochondrial membrane, however upon the collapse of MMP, JC-10 
will return to its monomeric green-fluorescent form [146]. 
For both cancer cells, the highest dye permeability was observed in GP-Cur-Ptx 
(Figure 16c, d), corroborating with the findings in ROS, which also scored the 
highest. Loss of MMP was dose-dependent for GP-Cur-Ptx in A549 cells and 
followed by 10-fold GP-Cur and 10-fold Cur. This indicates that the presence of Cur 
in these treatment groups has played a major role in disrupting the cells’ 
mitochondria. In comparison, the current GP-Cur-Ptx combined treatments induced  
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significantly higher depolarization of MMP than other reports, such as cocktail drug 
containing an antioxidant apigenin and paclitaxel [152]. As for MDA cells, GP-Ptx 
was equally effective as 10-fold Ptx in causing MMP loss. Additionally, it was also 
observed that GP-Cur-Ptx is as effective as 10-fold GP-Ptx in causing perturbation to 
the mitochondria of MDA cells, proving that the integrated combination treatment 
allows the usage of reduced dosages to attain the same therapeutic effects. 
 
3.9 Determination on the induction of apoptosis by GP-Cur-Ptx on A549 and 
MDA cells 
In order to quantify living cells from apoptotic and necrotic cells, double staining 
method was employed using Annexin Cy3 and 6-CFDA. Annexin Cy3 stains red on 
necrotic cells, by binding to phosphatidylserine which is present outside of plasma 
membrane of cells undergoing apoptosis. On the other hand, upon entering living 
cells, the non-fluorescent 6-CFDA is hydrolyzed by esters producing a green 
fluorescent product. Cells in the early stages of apoptosis, however, will be stained 
yellowish-green [153].  
A549 and MDA cells treated with GP-Cur-Ptx showed the highest apoptosis 
percentage (Figure 16e, f), which was in accordance with the highest ROS and highest 
loss of MMP observed. The induction of apoptosis was also dose-dependent as the 10-
fold treatment groups showed higher cell death compared to their respective IC50 
values. The hybrid treatment agents, GP-Cur and GP-Ptx were more potent in 
inducing apoptosis compared to single treatment of Cur and Ptx, even at 10-fold the 
concentration of the IC50 values. In order to further comprehend the apoptotic trend, 
the cellular morphology of the cells upon treatment was also investigated under the 
microscope.  
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Figure 18 Merged images of A549 (upper panel) and MDA (lower panel) cells after 
staining with Annexin-Cy3 and 6-CFDA with (a) un-treated cells, and cells treated 
with: (b) Cur; (c) Ptx; (d) GP-Cur; (e) GP-Ptx and (f) GP-Cur-Ptx. Arrows labelled 
‘A’ are representation of typical features of cells undergoing apoptosis. Cells that are 
green but show blebbing, cell-rupture or condensed and fragmented are taken as early 
stages of apoptosis, along with cells stained yellow in the merged images. 
Comparatively, cells stained red are regarded as necrotic [97]. Note: Cur: curcumin; 
GP: polymer-functionalized reduced graphene oxide; GP-Cur: Cur loaded onto GP; 
Ptx: paclitaxel; GP-Ptx: Ptx loaded onto GP; GP-Cur-Ptx: Cur and Ptx co-loaded onto 
GP. 
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For the untreated A549 and MDA cell lines, healthy cellular morphology without any 
abnormalities was observed and the cells were growing in close proximity (Fig. S3, 
S4). Upon treatment, obvious separation from the neighbouring cells was seen with a 
higher separation constituting to higher apoptotic cell death. Both cancer cell lines 
that received treatment with Cur showed obvious signs of cell shrinkage (Figure 18) 
[154, 97]. A similar finding was also observed for treatment with GP-Cur, along with 
the presence of yellowish-green in the merged images showing cells underwent early 
stages of apoptosis. In addition, treatment with GP-Cur severed the attachment of 
apoptotic cells from the surroundings cells.  
On the other hand, treatment with Ptx induced the cells to undergo necrosis as more 
rampant red-stain was observed [153,155]. Similarly, GP-Ptx showed the presence of 
necrosis, with treatment in MDA showing more rounded-up cells compared to in 
A549 cells. This is in accordance with the higher loss of MMP seen in GP-Ptx for 
MDA cells. On the contrary, GP-Ptx treatment on A549 cells induced obvious cell 
swelling. A549 and MDA cell lines treated with Ptx and GP-Ptx showed extensive 
plasma membrane blebbing, which is one of the late apoptotic characteristics. 
However, this was not found in cells treated with Cur and GP-Cur.  
Prominent features of cell apoptosis (shown by arrow) can be clearly seen in the GP-
Cur-Ptx treatments (Figure 18f). Cellular shrinkage and pyknosis, which are the 
results of nuclear membrane condensation into more densely packed material, were 
observed in both treated cancer cells. Additionally, separation from the surrounding 
cells took place and protrusions from plasma membrane or blebs, appeared more 
prominently in MDA cells.  It was reported that blebbing shows the presence of 
caspase activation involving a group of proteins which are crucial for programmed 
cell death [156,157]. Following this, disintegration of the nucleus into similarly dense 
and smaller particles takes place, forming apoptotic bodies or karyorrhexis [158,159]. 
This observation was found more obviously in A549 cells. GP-Cur-Ptx treatment on 
MDA cells caused late stages of apoptosis and necrosis, whereas A549 cells showed 
the characteristics of early stages of apoptosis. This finding could be translated to the 
higher level of ROS observed in MDA compared to A549 cell lines.  
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Based on these findings, it can be deduced that Ptx and GP-Ptx induced cell necrosis 
in A549 and MDA cells, which is unfavourable as the cells are passive victims due to 
the toxic process [159]. On the other hand, Cur and GP-Cur promotes cell apoptosis 
or programmed cell-death and with the introduction of Cur in the synergistic 
treatment, GP-Cur-Ptx, necrosis by Ptx has been completely suppressed, while 
promoting signal-dependent cell suicide, i.e. apoptosis.  
Based on the above findings, there is a consistent relationship between increased 
generations of ROS and increased loss of MMP that eventually lead to cell apoptosis 
and thus inhibition of cell proliferation. The sequence of these events is however, in 
need of further elucidation. Conceivably, it was reported that Cur and Ptx works 
synergistically in activating caspases, cleavage of Bid to tBid and mitochondrial 
release of cytochrome c, which consequently induce apoptosis by extrinsic and 
intrinsic pathways [160]. In addition, Cur promotes the down-regulation of Ptx 
activated-NFkB, which eventually contributes to Ptx-induced apoptosis on A549 and 
MDA cells [161]. 
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4.0 Conclusion and Recommendations 
 
An over the counter, commercial-grade mushroom powder was used to effectively 
reduce GO to RGO with a reaction time of approximately 1 h. This environmentally 
friendly method evades the use of chemicals and significantly reduces waste with the 
advantage of reusability of the extract as a reducing agent. The obtained RGO was 
readily dispersible in water and was reasonably small with the thickness of 1-2 nm 
and 181-500 nm in lateral dimension. The RGO obtained through this strategy is 
small as compared to other reported green-synthesis methods. In addition, solubility 
tests using various solvents showed that RGO is stable up one year. The synthesized 
RGO if highly biocompatible and has not shown any anti-proliferative effects towards 
colon and brain cancer as well as healthy cell lines. This makes the RGO suitable as a 
drug delivery carrier, especially for hydrophobic anticancer drugs. Polymer-
functionalization of RGO resulted in a GP cargo that further contributed to higher 
solubility and stability. Co-loading of Cur and Ptx onto the GP cargo has significantly 
increased the solubility of these 2 drugs and a remarkably high drug loading was also 
achieved, 678 wt.%, which to the best of our knowledge is the highest reported thus 
far for Cur. 
The synergistic system, GP-Cur-Ptx shows a dose dependent cytotoxicity against 
A549 and MDA cancer cells. For comparison, GP-Cur and GP-Ptx were also tested. 
GP-Cur and GP-Ptx were highly effective towards the inhibition of cancer cell 
growth, especially GP-Ptx, needing 8-23 fold lesser dose compared to Ptx alone. 
Upon introduction of only IC20 dose of Ptx to the GP-Cur system, a highly potent 
treatment system was created for both A549 and MDA cells with CI values <1, 
suggesting a synergistic system. The same concentration tested on normal cells shows 
no toxicity, demonstrating that the GP-Cur-Ptx system is cell-specific cytotoxic, 
especially to these two cancer cell lines.  Upon further elucidation, the highest ROS 
production was also observed in the GP-Cur-Ptx system, which was mainly due to the 
presence of Cur that acted as pro-oxidant and induced ROS accumulation in cells. 
ROS accumulation will eventually lead to polarization of the mitochondria and cell 
deaths, which is consistent to our findings. The percentage of apoptosis found after  
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treatment with GP-Cur, GP-Ptx and the combined GP-Cur-Ptx was significantly 
higher than treatments with one of the drugs, even with Cur and Ptx in 10-fold 
concentrations. Based on cell morphology, Ptx was found to induce late stages of 
apoptosis and necrosis in cells. However, in the combined treatment, cell necrosis by 
Ptx was significantly suppressed and the GP-Cur-Ptx majorly induced early stages of 
apoptosis. In addition, upon close examination, only the drugs were engulfed by cells, 
leaving behind the GP cargo. For future studies, further investigation is needed to 
determine the reaction pathways that are activated by the GP-Cur-Ptx system, other 
than the commonly reported for Cur and Ptx. The current findings seem promising for 
possibly future in vivo and clinical applications. 
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Supplementary Information 
 
Characterizations of Cur and Ptx loaded onto GP 
 
 
Fig. S1 Fluorescence spectra of Cur and Ptx loaded onto GP. 
Note: GP: polymer-functionalized RGO 
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Determination of ROS generation by treatment groups in A549 and MDA cells 
 
 
Fig. S2: ROS generation images of A549 (upper) and MDA-MB-231 (lower) of cells 
treated with media alone (Un-treated) and cells after treatment with GP-Cur, GP-Ptx 
and GP-Cur-Ptx for 120 min.  
Note: Cur: curcumin; GP: polymer-functionalized reduced graphene oxide; GP-Cur: 
Cur loaded onto GP; Ptx: paclitaxel; GP-Ptx: Ptx loaded onto GP; GP-Cur-Ptx:      
Cur and Ptx loaded onto GP.  
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Morphology of cells undergoing apoptosis in A549 cancer cells  
 
Fig. S3: Images of un-treated (Ut) A549 cells and A549 cells treated with Cur, Ptx, 
GP-Cur, GP-Ptx and GP-Cur-Ptx. The green fluorescent (left panel) represents the 
non-apoptotic cells. The red fluorescent (middle panel) represents necrotic cells and 
the yellowish-green fluorescent seen in the overlay images (right panel) represents 
early stages of apoptosis. Note: Cur: curcumin; GP: polymer-functionalized reduced 
graphene oxide; GP-Cur: Cur loaded onto GP; Ptx: paclitaxel; GP-Ptx: Ptx loaded 
onto GP; GP-Cur-Ptx: Cur and Ptx loaded onto GP. 
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Morphology of cells undergoing apoptosis in MDA cancer cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S4: Images of un-treated (Ut) MDA-MB-231 cells and MDA-MB-231 cells 
treated with Cur, Ptx, GP-Cur, GP-Ptx and GP-Cur-Ptx. The green fluorescent (left 
panel) represents the non-apoptotic cells. The red fluorescent (middle panel) 
represents necrotic cells and the yellowish-green fluorescent seen in the overlay 
images (right panel) represents early stages of apoptosis. Note: Cur: curcumin; GP: 
polymer-functionalized reduced graphene oxide; GP-Cur: Cur loaded onto GP; Ptx: 
paclitaxel; GP-Ptx: Ptx loaded onto GP; GP-Cur-Ptx: Cur and Ptx loaded onto GP.  
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